证券之星消息，丽珠集团(000513)02月14日在投资者关系平台上答复投资者关心的问题。 投资者：购买广东华南疫苗流感疫苗，RSV疫苗比流感疫苗更有价值为什么没有收购？

CSL Seqirus revenue is projected to benefit from the supply of H5 avian flu vaccines in the second half, with FLUAD launch preparations underway in Germany. CSL Vifor is set to maintain its ...

Vaccine aversion in the US has put a hole in CSL revenues in the first half, with the company saying the flu season is shaping up to be the worst in 15 to 20 years. But ironically, the company has ...

It also launched in Switzerland and listed on Australia's National Immunization Program. FLUAD. STIKO, Germany's highly influential technical advisory group, has given FLUAD a preferential ...

Revenue from CSL's flu vaccine-making business dropped sharply in the first half of the financial year amid a significant fall in immunisation rates, particularly in the US.

Revenue from CSL's flu vaccine-making business dropped sharply in the first half of the financial year amid a significant fall in immunisation rates, particularly in the US.

Revenue from CSL's flu vaccine-making business dropped sharply in the first half of the financial year amid a significant fall in immunisation rates, particularly in the US.

This chapter is maintained as an evergreen document, regularly reviewed and updated to reflect the most current information on active and passive immunizing agents authorized for use in Canada.